Please try another search
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy to treat tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. The company’s product candidates include RCH-01, a cell therapy for pattern baldness; RCS-01, a cell therapy foraging or sun damaged skin; and RCT-01, a cell therapy for tendon degeneration. It is also developing DermaPrecise, a dermal injection device. The company has a licensing and collaborative agreement with YOFOTO (China) Health Industry Co. Ltd. to develop and commercialize RCS-01, RCT-01, and DermaPrecise. RepliCel Life Sciences Inc. is based in Vancouver, Canada.
Name | Age | Since | Title |
---|---|---|---|
David M. Hall | 71 | 2010 | Independent Chairman of the Board |
Rolf Hoffmann | 62 | 2010 | Chief Medical Officer & Member of Clinical Advisory Board |
Peter Winston Lewis | 68 | 2011 | Independent Director |
R. Lee Buckler | 58 | 2014 | Director |
Ross G. Davidson | - | 2013 | Chairman of Clinical Advisory Board |
Jean Krutmann | - | - | Member of Clinical Advisory Board |
Andrew Schutte | 34 | 2018 | President, CEO & Director |
Tsukasa Kumai | - | - | Member of Clinical Advisory Board |
Akimichi Morita | - | 2021 | Member of Clinical Advisory Board |
Gary Boddington | 57 | 2021 | Independent Director |
Kunihiko Suzuki | 65 | 2021 | Senior Strategic Advisor to Directors |
Jamie MacKay | - | 2023 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review